Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER (PFE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Pfizer : UK gives Pfizer world's first over-the-counter Viagra approval

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/28/2017 | 05:04pm CEST
The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S.

LONDON (Reuters) - Pfizer's big-selling erectile dysfunction drug Viagra has been given a green light for sale without a prescription in Britain, the first country to grant it over-the-counter status.

The U.S. drugmaker said on Tuesday it was working on plans to launch the non-prescription version of the medicine, known as Viagra Connect, in the United Kingdom in the spring of 2018.

The drug will only be available in pharmacies and its supply will depend on pharmacists' assessment of its suitability for each individual.

Viagra has been one of the pharmaceutical industry's most successful prescription products since its launch in 1998, following a serendipitous discovery of its effects by researchers who had been studying it as a heart medicine.

It achieved peak worldwide sales of more than $2 billion in 2012 but sales have since declined as patents have expired, prompting Pfizer to explore extending its brand value as a non-prescription drug.

Viagra is so far the only erectile dysfunction medicine to be reclassified from "prescription only medicine" to "pharmacy" status in Britain. The change follows a lengthy review by the Medicines and Healthcare products Regulatory Agency (MHRA).

Pfizer will continue to make Viagra available as a prescription drug but the option of also buying it over-the-counter is likely to reduce demand for potentially ineffective and dangerous fakes.

"It's important men feel they have fast access to quality and legitimate care, and do not feel they need to turn to counterfeit online supplies which could have potentially serious side effects," said Mick Foy, the MHRA's group manager in vigilance and risk management of medicines.

(Reporting by Ben Hirschler; Editing by Alexander Smith and Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
07:30pFDA OKs Pfizer's Talzenna, Myriad Test in Form of Breast Cancer -- Update
DJ
07:10pPFIZER : FDA OKs Pfizer's Talzenna, Myriad Test in Form of Breast Cancer
DJ
06:18pPFIZER : U.S. FDA Approves TALZENNA® (talazoparib)
PU
07:11aPFIZER : May's new merger powers would be a hostile takeover by the state
AQ
10/12Not for profit, but for the greater good
AQ
10/12Not for profit, but for the greater good
AQ
10/12PFIZER : 3 Lifestyle Changes for Better Liver Health
PU
10/11PFIZER : to Pay $700,000 to Settle Probe Into Ad Practices -- Update
DJ
10/11PFIZER : to Pay $700,000 to Settle Probe Into Ad Practices
DJ
10/11PRESS RELEASE : A.G. Underwood Announces Settlement With Pfizer For Deceptive Ad..
DJ
More news
News from SeekingAlpha
12:37pFDA OKs Myriad's BRACAnalysis CDx as a companion diagnostic for Pfizer's Talz.. 
10/15FDA issues new guidance aimed at more efficient drug development 
10/14CATALYST BIOSCIENCES : Rare Risk/Reward Opportunity 
10/14A Company In Decline? The Case For/Against Affimed After Bad News 
10/12MY RETIREMENT PORTFOLIO : 5.75% Income, But Capital Is At Greater Risk 
Financials ($)
Sales 2018 54 176 M
EBIT 2018 20 523 M
Net income 2018 13 059 M
Debt 2018 26 440 M
Yield 2018 3,18%
P/E ratio 2018 19,20
P/E ratio 2019 17,51
EV / Sales 2018 5,23x
EV / Sales 2019 5,07x
Capitalization 257 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 18
Average target price 42,5 $
Spread / Average Target -1,5%
EPS Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer & Director
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER20.87%256 643
JOHNSON & JOHNSON-4.19%359 141
NOVARTIS0.07%212 170
ROCHE HOLDING LTD.-4.56%204 254
MERCK AND COMPANY23.44%185 661
AMGEN12.47%127 765